Stock BCRX BIOCRYST PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
5.32 USD -0.37% Intraday chart for BioCryst Pharmaceuticals, Inc. +19.55% -11.19%
May. 09 BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO CI
May. 07 JMP Securities Adjusts Price Target on BioCryst Pharmaceuticals to $15 From $14, Maintains Market Outperform Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
BioCryst Pharmaceuticals Shares Jump After Q1 Beat
Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency
BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows as Revenue Increases
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
BioCryst Launches Orladeyo (Berotralstat) in Italy
BioCryst Pharmaceuticals Sees FY23, FY24 Orladeyo Sales Topping Prior Forecast; Eyes 2024 Operating Profit
BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024
BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)
Koersalarm: aandeel Pharvaris blijft stijgen
Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023
BioCryst Amends Deal With Torii Pharmaceutical for Orladeyo's Commercialization in Japan; Shares Rise
BioCryst Pharmaceuticals Receives Argentine Regulatory Approval for Orladeyo
Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina
BioCryst Pharmaceuticals Says Hereditary Angioedema Treatment Gets Marketing Authorization in Spain
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCRX Stock
  4. News BioCryst Pharmaceuticals, Inc.
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW